Sun Pharma takes aim at a crowded market with another IL-23 psoriasis drug from Merck
In the last minute, late-stage race to the market with a new round of psoriasis drugs, India’s Sun Pharmaceuticals is making its own bid with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
